ArticleBioorganic & medicinal chemistry letters2013
Synthesis of azide derivative and discovery of glyoxalase pathway inhibitor against pathogenic bacteria.
Article in Bioorganic & medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 32 citations in OpenAlex.
- Photoinduced, Copper-Catalyzed Enantioconvergent Azidation of Alkyl Halides.Journal of the American Chemical Society · 2025Article
- Article
- Comprehensive Examination of the Mouse Lung Metabolome FollowingJournal of proteome research · 2020Article
- Divergent synthesis of chiral cyclic azides via asymmetric cycloaddition reactions of vinyl azides.Nature communications · 2019Article
- Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway.Redox biology · 2018Review
- Flavonoid Enhances the Glyoxalase Pathway in Cerebellar Neurons to Retain Cellular Functions.Scientific reports · 2017Article
- Discovery of bicyclic inhibitors against menaquinone biosynthesis.Future medicinal chemistry · 2016Article
- Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Scientific reports · 2015Article
- Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A glyoxalase inhibitor was synthesized and tested against Staphylococcus aureus for first time and showed MIC90 of 20 μg/ml. Henceforth, we synthesized unnatural azide derivative of the same inhibitor to improve the biological activity. In that order, an azide carboxylate was synthesized from dimethyl tartrate by tosylation and azide substitution. The synthesized, azide compound was coupled with glutathione derivative in high yield and tested against S. aureus and showed improved MIC90 of 5 μg/ml. In general, it can be also easily converted to unnatural β-amino acid in good yield. The shown methodology will be extended to study induced suicide in Burkholderia mallei, Francisella tularensis and Mycobacterium tuberculosis in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.